Caxton Associates LP Decreases Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Caxton Associates LP decreased its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 32.0% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 51,568 shares of the biotechnology company's stock after selling 24,280 shares during the period. Caxton Associates LP's holdings in ADMA Biologics were worth $884,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ADMA. Bank of America Corp DE lifted its holdings in shares of ADMA Biologics by 59.7% during the 4th quarter. Bank of America Corp DE now owns 766,224 shares of the biotechnology company's stock valued at $13,141,000 after acquiring an additional 286,569 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in shares of ADMA Biologics by 14.1% during the fourth quarter. Ameriprise Financial Inc. now owns 715,672 shares of the biotechnology company's stock worth $12,274,000 after purchasing an additional 88,542 shares in the last quarter. Algert Global LLC boosted its position in shares of ADMA Biologics by 33.3% in the fourth quarter. Algert Global LLC now owns 272,349 shares of the biotechnology company's stock worth $4,671,000 after buying an additional 67,961 shares during the period. Freestone Grove Partners LP purchased a new stake in shares of ADMA Biologics during the 4th quarter valued at about $769,000. Finally, Northern Trust Corp lifted its position in ADMA Biologics by 6.0% during the 4th quarter. Northern Trust Corp now owns 2,575,075 shares of the biotechnology company's stock worth $44,163,000 after acquiring an additional 145,387 shares in the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Trading Down 2.4 %

Shares of ADMA opened at $23.15 on Wednesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a one year low of $6.72 and a one year high of $25.67. The stock has a 50-day moving average price of $19.91 and a 200 day moving average price of $18.62. The company has a market capitalization of $5.50 billion, a P/E ratio of 82.67 and a beta of 0.57.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.